Replies to post #212348 on Biotech Values

[jbog]

NVS—ODAC votes 10-0 in favor of CTL019—(CAR-T)—in pediatric ALL:

Bloomberg has a interesting story on this landmark drug.

Besides the approx $500k for the initial treatment, the patients immune system will be crippled. The patients will need boosting immunoglobulin treatment every 3 to 4 weeks (possibly for life) at a cost of about $10K per treatment.



https://www.bloomberg.com/news/articles/2017-07-12/cancer-breakthrough-near-fda-approval-carries-costly-side-effect